Tolerance induction using the Malmo treatment model 1982-1995

Haemophilia

Volumn 5, Issue 1, 1999, Pages 32-39

  Freiburghaus, C ^a,b,c   Berntorp, E ^a   Ekman, M ^a   Gunnarsson, M ^a   Kjellberg, B M ^b   Nilsson, I M ^a  

^a LUND UNIVERSITY   (Sweden)

^b Excorim AB   (Sweden)

^c Box 10101   (Sweden)

Author keywords

Factor IX; Factor VIII; Haemophilia; Inhibitors; Tolerance induction

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; INTRAVENOUS DRUG ADMINISTRATION; MODEL; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DRUG TOLERANCE; GAMMA-GLOBULINS; HALF-LIFE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; INFANT; MIDDLE AGED; SWEDEN;

EID: 0033041458     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1999.00195.x     Document Type: Article

References (32)

1. Shapiro SS. Antibodies to blood coagulation factors. Clin Haematol 1979; 8: 207-14.
2. Proceeding from II International Workshop on Immune Tolerance in Haemophilia. Vox Sang, in press.
3. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg BM, Nilsson IM. Immunoadsorption for removal of inhibitors: Update on treatments in Malmö-Lund between 1980 and 1995. Haemophilia 1998; 4: 16-20.
4. Lusher JM. NovoSeven Compassionate Use Investigators. Recombinant factor Vila (NovoSeven) in the treatments of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996; 26: 124-30.
5. Shapiro AD. American experience with home use of NovoSeven: recombinant factor Vila in hemophiliacs with inhibitors. Haemostasis 1996; 26: 143-9.
6. Nilsson IM, Berntorp E, Freiburghaus C. Treatment of patients with factor VIII and IX inhibitors. Thromb Haemost 1993; 70: 1 56-9.
7. Nilsson IM, Freiburghaus C. Apheresis. In: Aledort LM, et al., eds. Inhibitors to Coagulation Factors. New York: Plenum Press, 1995.
8. Nilsson IM. The management of hemophilia patients with inhibitors. Transfus Med Rev 1992; 4: 4 285-93.
9. Nilsson IM, Jonsson S, Sundqvist S-B, Ahlberg Å, Bergentz S-E. A procedure for removing high titer antibodies by extracorporeal protein-A-sepharose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies. Blood 1981; 58: 38-44.
10. Nilsson IM, Sundqvist S-B, Ljung R, Holmberg L, Freiburghaus C, Björling G. Suppression of secondary antibody response by intravenous immunoglobulin in a patient with haemophilia B and antibodies. Scand J Haematol 1983; 30: 458-64.
11. Nilsson IM, Hedner U. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scand J Haematol 1976; 16: 369.
12. Wallmark A, Ljung R, Nilsson IM, Holmberg L, Hedner U, Lindvall M, Sjögren H-O. Polymorphism of normal factor IX detected by mouse monoclonal antibodies. Proc Natl Acad Sci USA, 1985; 82: 3839.
13. Nilsson IM, Kirkwood TBL, Barrowcliffe TW. In vivo recovery of factor VIII. A comparison of one-stage and two-stage assay methods. Thromb Haemostas 1979; 42: 123.
14. Nilsson IM, Berntorp E, Rickard RA. Results in three Australian haemophilia B patients with high-responding inhibitors treated with the Malmö model. Haemophilia 1995; 1: 59-66.
15. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1228-31.
16. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high dose intravenous gammaglobulin. N Engl J Med 1982; 306: 1254-8.
17. Lusher JM, Iyer R, Evans RK. Effective suppression of factor VIII antibodies in patients with haemophilia A with cyclophosphamide. VII Congress of the World Federation of Haemophilia, Teheran 1971; 272-74.
18. Nilsson IM, Hedner U. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scand J Haematol 1976; 16: 369-82.
19. Hedner U, Tengborn L. Management of haemophilia A with antibodies - the effect of combined treatment with factor VIII, hydrocortisone and cyclophosphamide. Thromb Haemostas 1985; 54: 776-9.
20. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N Engl J Med 1988; 318: 947-50.
21. Bray GL, Kroner BL, Arkin S, Aledort LW, Hilgartner MW, Eyster ME, Ragni MV, Goedner JJ. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection, a report from the multi-center hemophilia cohort study. Am J Hematol 1993; 42: 375-9.
22. Kucharski W, Scharf R, Nowak T. Immune tolerance induction in haemophiliacs with inhibior to FVIII. high- or low-dose programme. Haemophilia 1996; 2: 224-228.
23. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 3 983-8.
24. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia - principal results from the International Registry. Thromb Haemostas 1994; 72: 1 155-8.
25. Kreuz W, Ehrenforth S, Funk M, et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1: 24-32.
26. Sultan Y, Kazachkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; ii: 765-8.
27. Sultan Y, Kazachkine MD, Nydegger U, Rossi F, Dietrich G, Algiman M. Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII.c inhibitors. Am J Med 1991; 91 (Suppl. 5A), 35S-39S.
28. Hudak C, Spiridonidis CH, Hart AJ, Betras SA, Laufman LR. Pregnancy-associated factor VIII inhibitors: treatment with intravenous high-dose immunoglobulin. Am J Hematol 1993; 43: 158.
29. Kazatchkine MD, Kaveri SS, Ntdegger UE, Sultan Y. Variable (V) region - mediated control of autoreactivity to factor VIII. In: Aldort LM, et al, eds. Inhibitors to Coagulation Factors. New York: Plenum Press, 1995.
30. Gilles JG, Saint-Remy J-M. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clinic Invest 1994; 94: 1496-505.
31. Nilsson IM, Berntorp E, Zettervall O. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies. Proc Natl Acad Sci USA 1986; 83: 9169-73.
32. Nilsson IM, Berntorp E, Zettervall O, Dahlbäck B. Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients. Blood 1990; 68: 537-40.